- Assembly Biosciences Inc Extraordinary Shareholders Meeting TranscriptJan 31, 2024
- Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call TranscriptOct 17, 2023
- Assembly Biosciences Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 25, 2023
- Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call TranscriptAug 31, 2022
- Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call TranscriptJul 26, 2022
- Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call TranscriptMar 31, 2022
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Assembly Biosciences Inc Earnings Call TranscriptFeb 25, 2021$66.36 (-1.95%)Earnings
- Assembly Biosciences, Inc. - Special Call TranscriptNov 05, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptJul 20, 2020
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2020
- Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call TranscriptMay 07, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptNov 11, 2019
- Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call TranscriptApr 15, 2019
Assembly Biosciences, Inc. - Special Call Transcript
Good morning, and welcome to the Assembly Biosciences conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the call over to Lauren Glaser, Senior Vice President of Investor Relations and Corporate Affairs for Assembly. Please go ahead.
Thank you, Bridget. Good morning, and thank you for joining us on such short notice. Today's announcement of our strategic collaboration with BeiGene is an exciting and significant milestone for Assembly. This collaboration provides a strong foundation to accelerate the development in China of our hepatitis B portfolio, which currently consists of 3 clinical stage core inhibitors: ABI-H0731 and ABI-H2158, which are in ongoing Phase II clinical trials, and ABI-H3733, which is in Phase I development.
The press release and the slides we will refer to during the call are available in the News and Events section of our corporate website at
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)